Back to Journals » International Journal of Nanomedicine » Volume 17
Comments on “Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer” [Letter]
Authors Wang X
Received 5 January 2022
Accepted for publication 14 February 2022
Published 6 April 2022 Volume 2022:17 Pages 1633—1634
Checked for plagiarism Yes
Editor who approved publication: Dr Yan Shen
The First Affiliated Hospital of Nanchang University, Nanchang, 330006, People’s Republic of China
Correspondence: Xin Wang, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, People’s Republic of China, Email [email protected]
View the original paper by Dr Ren and colleagues
I have read a study entitled “Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer” in International Journal of Nanomedicine.1 This study showed Emodin-Conjugated Fe3O4 Nanoparticles can be applied for pancreatic cancer imaging and therapy. There may be several issues requiring attention. First, it was surprising that the inhibition rates of Fe3O4-PEG-Cy7-EMO on hTERT-HPNE cells (normal pancreatic cells) were so high in Figure 5A, 60% at 80 μg/mL and 70% at 100 μg/mL. However, the apoptosis or necrosis rate was lower than 10% as shown in Figure 5B. If Fe3O4-PEG-Cy7-EMO has such high toxicity to normal cells, the applicable potential is low. There may be an error in one of the data. For cell viability assay, 6 μg/mL was not shown in “Methods (0, 12.5, 25, 50, 80, 100 µg/mL)”, but it was shown in Figure 5A. The authors should recheck their original data. Another issue is the fluorescence imaging of liver in Figure 6E and 6F at 6 h. Figure 6E shows a very low signal in liver at 6 h. However, moderate fluorescent signal in liver was observed in Figure 6F. In flow cytometer (FCS) analysis, the data shown in Figure 5B was equal to the data in Table 1 except for apoptosis rate of BxPc3 treated with Fe3O4-PEG-Cy7-EMO at 80 μg/mL. What was the sample size? The authors did not show information about sample size. Did they perform the FCS experiment only once? If they performed two or more experiments, the data in Figure 5B and Table 1 should not be the same. Moreover, there are overlapped images in Figure 7A. The last two images for spleen were from same image.
The author reports no conflicts of interest in this communication.
1. Ren S, Song L, Tian Y, et al. Emodin-conjugated PEGylation of Fe(3)O(4) nanoparticles for FI/MRI dual-modal imaging and therapy in pancreatic cancer. Int J Nanomed. 2021;16:7463–7478. doi:10.2147/IJN.S335588
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.